An investigational procedure—duodenal mucosal resurfacing (DMR)—is emerging as a potential solution to one of the biggest challenges in obesity care: what happens after GLP-1s are stopped.
In a randomized, sham-controlled trial, patients who discontinued GLP-1 therapy typically regained weight—but those who underwent DMR maintained the majority of their weight loss, with significantly less rebound at six months. The procedure works by ablating the duodenal mucosa, targeting a region increasingly recognized as central to metabolic regulation.
This directly addresses a growing real-world problem: while GLP-1 drugs are highly effective, 60–70% of patients discontinue them within a year due to cost, side effects, or long-term adherence challenges. DMR introduces a fundamentally different approach—not replacing GLP-1s, but extending their benefit after discontinuation.